CD8A and cancer: In pre-clinical cancer models, Lag-3 expression has been found to be co-expressed with PD-1 on tumor-infiltrating CD4+ and CD8+ T cells and co-blockade of Lag-3 and PD-1 can improve the proliferation and cytokine production of tumor-antigen specific CD8+ T cells (31).